This trial identified a population of patients with HPV-associated cancer with promising antitumor responses and improved survival, supporting further evaluation of PDS0101, PDS01ADC, and simultaneous PD-L1/TGF-β inhibition in patients with HPV-16–positive tumors. The gene discussed is TGFB1; the disease is cancer.